Ultragenyx Pharmaceutical Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
RARE Nasdaq 2830 www.ultragenyx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ultragenyx Pharmaceutical Inc.

Sector Update: Healthcare Stocks Softer Monday Afternoon - Oct 19th, 2026 11:52 am
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week - Oct 15th, 2026 7:33 am
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? - Oct 14th, 2026 7:30 am
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million - Oct 14th, 2026 6:30 am
FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts - Oct 9th, 2026 9:18 am
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Oct 8th, 2026 7:49 am
Is Ultragenyx Pharmaceutical (RARE) Undervalued Following EMA Validation For Its Sanfilippo Gene Therapy? - Oct 8th, 2026 4:08 am
Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million - Oct 7th, 2026 10:00 am
Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity - Oct 7th, 2026 9:51 am
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million - Oct 7th, 2026 6:30 am
MARKETS LIVE: Wall Street ends lower as 30-year Treasury yield hits 2002 high - Oct 7th, 2026 5:10 am
Ultragenyx (RARE) EMA Validation of MPS IIIA Gene Therapy: Inflection Point or Incremental Milestone? - Oct 6th, 2026 6:16 pm
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation - Oct 5th, 2026 8:46 am
Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A) - Oct 2nd, 2026 12:00 am
RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results - Sep 22nd, 2026 1:09 pm
FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target? - Sep 22nd, 2026 4:18 am
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI - Sep 19th, 2026 8:10 am
RARE Stock Up 13% on FDA Approval of Sanfilippo Syndrome Gene Therapy - Sep 18th, 2026 8:49 am
/C O R R E C T I O N -- Andelyn Biosciences/ - Sep 18th, 2026 7:00 am
Ultragenyx Gets A ‘Much-Needed Win,’ Says Cantor – Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy - Sep 18th, 2026 6:16 am